SGLT2 inhibitor lowers risk of kidney failure in type 2 diabetes
Results showed that canagliflozin improved outcomes in type 2 diabetes patients with kidney disease, preventing kidney failure, heart failure and cardiovascular events
Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) have a lower risk of kidney failure and cardiovascular events if they are treated with canagliflozin, research has confirmed.
To investigate, researchers in Sydney, Australia, randomly assigned 4,401 patients with T2DM and CKD to either 100mg of canagliflozin — a sodium glucose cotransporter 2 (SGLT2) inhibitor — or placebo.
All participants were already being treated with renin angiotensin system blockade and were followed up for a median of 2.6 years.
Results showed that people taking canagliflozin were 30% less likely than those taking placebo to experience the primary outcome, a composite of end-stage kidney disease; a doubling of the serum creatinine level, which can highlight worsening kidney function; or death from kidney or cardiovascular causes.
Event rates were 43.2 per 1,000 patient years in the canaglifozin group and 61.2 per 1,000 patient-years in the placebo group (hazard ratio [HR] 0.70; 95% confidence interval [CI] 0.59–0.82; P=0.00001).
When kidney-specific outcomes were evaluated, the risk was lowered by 34% (HR 0.66; 95% CI 0.53–0.81; P<0.001).
Vlado Perkovic, lead author and professor of medicine at the George Institute for Global Health, said: “[The] trial provides convincing evidence that canagliflozin improves outcomes in diabetes with kidney disease, preventing kidney failure, heart failure and cardiovascular events.”
Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206795
Recommended from Pharmaceutical Press
This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.£43.00
An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.£54.00
An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.£33.00
Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.£43.00
All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.£27.00